Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Chronic myeloid leukemia is a well known disease. The must targeted treatments are the tyrosine kinas inhibitors. The inhibitory action on the anarchic proliferation of cells seems to be the best method to delay or stop the evolution of disease. The Glivec® is the paradigm in CML treatment. The discovery of this compound has considerably elevated the life level of patients suffering from chronic myeloid leukemia. Other tki showed their effectiveness, including nilotinib and dasatinib. Nevertheless, such patients develop resistance mechanism against tki. The bypass of these resistance mechanisms raises a lot of interest office of scientists La leucémie myéloïde chronique est une maladie relativement bien connue. Les traitements les plus ciblés actuellement sont les inhibiteurs des tyrosines kinases. En effet, l’action inhibitrice sur la prolifération anarchique des cellules s’avère être la méthode la plus efficace pour retarder ou stopper l’évolution de la maladie. Le paradigme du traitement de la LMC est le Glivec®. La découverte de ce médicament a considérablement augmenté le niveau de vie des patients souffrant de leucémie myéloïde chronique. D’autres inhibiteurs de tyrosine kinase (tki) ont montré leur efficacité, c’est le cas par exemple du nilotinib et du dasatinib. Cependant, chez certains patients, on voit apparaître des mécanismes de résistance aux inhibiteurs de tyrosine kinase. Le détournement de ces mécanismes de résistance suscite beaucoup d’intérêt auprès des chercheurs

Leukemia, Myelogenous, Chronic, BCR-ABL Positive --- antagonists and inhibitors --- imatinib

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cytotoxicity, Immunologic --- Leukemia, Myelogenous, Chronic, BCR-ABL Positive --- Antigens, CD34 --- Hematopoietic Stem Cell Transplantation --- Leukemia, Myelogenous, Chronic, BCR-ABL Positive --- therapy --- metabolism --- immunology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Protein Kinase Inhibitors --- Leukemia, Myelogenous, Chronic, BCR-ABL Positive --- Signal Transduction --- Leukemia, Myeloid, Acute --- therapeutic use --- drug therapy --- pathology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML. Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.

Chronic myeloid leukemia --- Pathology --- Protein Kinase Inhibitors --- Genetics --- Antineoplastic Agents --- Drug Therapy --- Leukemia, Myelogenous, Chronic, BCR-ABL Positive --- Leukemia, Myeloid --- Medicine --- Therapeutics --- Enzyme Inhibitors --- Therapeutic Uses --- Biology --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Health Occupations --- Molecular Mechanisms of Pharmacological Action --- Biological Science Disciplines --- Pharmacologic Actions --- Leukemia --- Disciplines and Occupations --- Natural Science Disciplines --- Neoplasms by Histologic Type --- Chemical Actions and Uses --- Neoplasms --- Chemicals and Drugs --- Diseases --- Health & Biological Sciences --- Molecular aspects --- Molecular aspects. --- Treatment. --- Leucaemia --- Leucemia --- Leucocythaemia --- Leucocythemia --- Leucosis --- Leukaemia --- Leukosis --- Chronic granulocytic leukemia --- Chronic myelocytic leukemia --- Chronic myelogenous leukemia --- CML (Disease) --- Anemia --- Cancer --- Leucocytosis --- Preleukemia --- Chronic leukemia --- Myeloid leukemia --- Hematology. --- Oncology  . --- Oncology. --- Tumors --- Haematology --- Internal medicine --- Blood